Form 4: National HealthCare Corp CEO Stephen Flatt Reports Stock Grant and Option Awards
SEC Form 4 Filing
CEO Stephen Flatt reports the grant of restricted shares and stock options in National HealthCare Corp.
Summary
- Stephen Flatt, CEO of National HealthCare Corp, filed a Form 4 disclosing transactions related to the company's stock.
- On March 5, 2025, Mr. Flatt was granted 2,914 shares of common stock.
- These shares are restricted and will vest in three equal installments on January 1, 2026, January 1, 2027, and January 1, 2028.
- Mr. Flatt also holds options to purchase common stock at various exercise prices and expiration dates.
- These include options for 4,734 shares at $63.96 expiring on February 18, 2027, 10,000 shares at $53.94 expiring on March 8, 2028, 15,000 shares at $94.1 expiring on March 5, 2029, and 18,000 shares at $90.62 expiring on February 28, 2030.
- Following the reported transactions, Mr. Flatt beneficially owns 57,579 shares of common stock.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management with shareholder interests.
Positives
- The grant of restricted stock aligns the CEO's interests with those of the shareholders, incentivizing long-term value creation.
- The vesting schedule of the restricted shares encourages continued service and commitment from the CEO.
Industry Context
Executive compensation packages often include stock options and restricted stock to align management's interests with those of shareholders, a common practice in the healthcare industry.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages across the healthcare industry.
- Companies like Brookdale Senior Living and HCA Healthcare also utilize stock options and restricted stock units to incentivize their executives.
- The vesting schedules and exercise prices are generally in line with industry norms for companies of similar size and market capitalization.
Stakeholder Impact
- Shareholders may view the stock and option grants positively as they incentivize the CEO to increase shareholder value.
- Employees may see the grants as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| November 22, 2023 | Date of Power of Attorney execution. |
| February 18, 2023 | Date of option grant with expiration on February 18, 2027, exercise price $63.96. |
| March 8, 2024 | Date of option grant with expiration on March 8, 2028, exercise price $53.94. |
| March 5, 2025 | Date of restricted stock grant and option grant with expiration on March 5, 2029, exercise price $94.1. |
| March 5, 2025 | Date of Form 4 filing. |
| February 28, 2026 | Date of option grant with expiration on February 28, 2030, exercise price $90.62. |
| January 1, 2026 | First vesting date (33 1/3%) of restricted shares. |
| January 1, 2027 | Second vesting date (33 1/3%) of restricted shares. |
| January 1, 2028 | Final vesting date (33 1/3%) of restricted shares. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.